Shares of Akari Therapeutics PLC (NASDAQ:AKTX) have been given a consensus broker rating score of 2.00 (Buy) from the two brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company.
Brokerages have set a one year consensus price objective of $2.50 for the company and are forecasting that the company will post ($1.00) EPS for the current quarter, according to Zacks. Zacks has also given Akari Therapeutics an industry rank of 161 out of 265 based on the ratings given to related companies.
Several equities analysts have recently commented on AKTX shares. ValuEngine upgraded Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 30th. Zacks Investment Research cut Akari Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Canaccord Genuity restated a “buy” rating and set a $15.00 target price on shares of Akari Therapeutics in a report on Friday, September 22nd. William Blair upgraded Akari Therapeutics from a “market perform” rating to an “outperform” rating in a report on Friday, September 22nd. Finally, Chardan Capital restated a “neutral” rating on shares of Akari Therapeutics in a report on Sunday, September 17th.
Shares of Akari Therapeutics (AKTX) traded down $0.11 during trading on Friday, hitting $3.95. The stock had a trading volume of 388,142 shares, compared to its average volume of 326,619. The company has a market cap of $60.26, a price-to-earnings ratio of -1.47 and a beta of -8.64. Akari Therapeutics has a 12-month low of $3.18 and a 12-month high of $22.20.
COPYRIGHT VIOLATION NOTICE: This article was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2018/01/13/zacks-akari-therapeutics-plc-aktx-given-2-50-average-target-price-by-analysts.html.
About Akari Therapeutics
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Akari Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Akari Therapeutics and related companies.